150 related articles for article (PubMed ID: 32304412)
1. High expression of TRAF4 predicts poor prognosis in tamoxifen-treated breast cancer and promotes tamoxifen resistance.
Zhou J; Li W; Ming J; Yang W; Lu L; Zhang Q; Ruan S; Huang T
Anticancer Drugs; 2020 Jul; 31(6):558-566. PubMed ID: 32304412
[TBL] [Abstract][Full Text] [Related]
2. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
3. SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
Larsen SL; Laenkholm AV; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
PLoS One; 2015; 10(2):e0118346. PubMed ID: 25706943
[TBL] [Abstract][Full Text] [Related]
4. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q
Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135
[TBL] [Abstract][Full Text] [Related]
5. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
Li J; Lu M; Jin J; Lu X; Xu T; Jin S
Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
[TBL] [Abstract][Full Text] [Related]
6. Dynamic surveillance of tamoxifen-resistance in ER-positive breast cancer by CAIX-targeted ultrasound imaging.
Li Y; Chen X; Zhou Z; Li Q; Westover KD; Wang M; Liu J; Zhang S; Zhang J; Xu B; Wei X
Cancer Med; 2020 Apr; 9(7):2414-2426. PubMed ID: 32048471
[TBL] [Abstract][Full Text] [Related]
7. Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.
Alfarsi LH; El-Ansari R; Craze ML; Masisi BK; Mohammed OJ; Ellis IO; Rakha EA; Green AR
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093034
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of TRAF4 targeting RSK4 inhibits proliferation, invasion and metastasis in breast cancer xenografts.
Zhu L; Zhang S; Huan X; Mei Y; Yang H
Biochem Biophys Res Commun; 2018 Jun; 500(3):810-816. PubMed ID: 29684350
[TBL] [Abstract][Full Text] [Related]
9. Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer.
Wang Y; Gong X; Zhang Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34406386
[TBL] [Abstract][Full Text] [Related]
10. TRAF4, a new substrate of SIAH1, participates in chemotherapy resistance of breast cancer cell by counteracting SIAH1-mediated downregulation of β-catenin.
Ren H; Mi X; Zhao P; Zhao X; Wei N; Huang H; Meng Z; Kou J; Sun M; Liu Y; Zhang H; Yang J; Li W; Li H
Breast Cancer Res Treat; 2020 Sep; 183(2):275-289. PubMed ID: 32671611
[TBL] [Abstract][Full Text] [Related]
11. Expression and clinicopathological significance of DNA methyltransferase 1, 3A and 3B in tamoxifen-treated breast cancer patients.
Jahangiri R; Jamialahmadi K; Gharib M; Emami Razavi A; Mosaffa F
Gene; 2019 Feb; 685():24-31. PubMed ID: 30359738
[TBL] [Abstract][Full Text] [Related]
12. Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically.
Morgan L; Gee J; Pumford S; Farrow L; Finlay P; Robertson J; Ellis I; Kawakatsu H; Nicholson R; Hiscox S
Cancer Biol Ther; 2009 Aug; 8(16):1550-8. PubMed ID: 19830888
[TBL] [Abstract][Full Text] [Related]
13. SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization.
Yi P; Xia W; Wu RC; Lonard DM; Hung MC; O'Malley BW
Genes Dev; 2013 Feb; 27(3):274-87. PubMed ID: 23388826
[TBL] [Abstract][Full Text] [Related]
14. TRAF4 promotes tumorigenesis of breast cancer through activation of Akt.
Zhang J; Li X; Yang W; Jiang X; Li N
Oncol Rep; 2014 Sep; 32(3):1312-8. PubMed ID: 24993240
[TBL] [Abstract][Full Text] [Related]
15. CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.
Wu M; Soler DR; Abba MC; Nunez MI; Baer R; Hatzis C; Llombart-Cussac A; Llombart-Bosch A; Aldaz CM
Mol Cancer Res; 2007 Dec; 5(12):1285-95. PubMed ID: 18171986
[TBL] [Abstract][Full Text] [Related]
16. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
17. Circular RNA‑MTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4/Eg5 axis.
Liu Y; Dong Y; Zhao L; Su L; Luo J
Int J Oncol; 2018 Oct; 53(4):1752-1762. PubMed ID: 30015883
[TBL] [Abstract][Full Text] [Related]
18. Reduced Expression of
Yan X; Gao Z; Zhang L; Chen C
Anticancer Agents Med Chem; 2023; 23(8):929-937. PubMed ID: 36537604
[TBL] [Abstract][Full Text] [Related]
19. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.
Ghayad SE; Vendrell JA; Bieche I; Spyratos F; Dumontet C; Treilleux I; Lidereau R; Cohen PA
J Mol Endocrinol; 2009 Feb; 42(2):87-103. PubMed ID: 18984771
[TBL] [Abstract][Full Text] [Related]
20. Increased Expression of Gankyrin and Stemness Factor Oct-4 are Associated with Unfavorable Clinical Outcomes and Poor Benefit of Tamoxifen in Breast Carcinoma Patients.
Jahangiri R; Mosaffa F; EmamiRazavi A; Gharib M; Jamialahmadi K
Pathol Oncol Res; 2020 Jul; 26(3):1921-1934. PubMed ID: 31853860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
